NASDAQ:DRNA Dicerna Pharmaceuticals Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dicerna Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $18.61 -1.24 (-6.25 %) (As of 09/21/2020 12:00 AM ET) Add Compare Share Today's Range$18.57Now: $18.61▼$19.7250-Day Range$17.13MA: $19.07▼$22.9052-Week Range$11.75Now: $18.61▼$27.68Volume714,001 shsAverage Volume671,659 shsMarket Capitalization$1.39 billionP/E RatioN/ADividend YieldN/ABeta1.56 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingDicerna Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $35.30, Dicerna Pharmaceuticals has a forecasted upside of 89.7% from its current price of $18.61.Amount of Analyst CoverageDicerna Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesDicerna Pharmaceuticals has received 432 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDicerna Pharmaceuticals has received 288 “underperform” votes. (Add your “underperform” vote.)Community SentimentDicerna Pharmaceuticals has received 60.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote “Outperform” if you believe DRNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDicerna Pharmaceuticals does not currently pay a dividend.Dividend GrowthDicerna Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dicerna Pharmaceuticals insiders have sold 240.28% more of their company's stock than they have bought. Specifically, they have bought $180,600.00 in company stock and sold $614,541.00 in company stock.Percentage Held by InsidersOnly 11.30% of the stock of Dicerna Pharmaceuticals is held by insiders.Percentage Held by Institutions83.50% of the stock of Dicerna Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dicerna Pharmaceuticals are expected to grow in the coming year, from ($0.69) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dicerna Pharmaceuticals is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dicerna Pharmaceuticals is -10.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDicerna Pharmaceuticals has a P/B Ratio of 8.38. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRNA Previous Symbol CUSIPN/A CIK1399529 Webwww.dicerna.com Phone617-621-8097Debt Debt-to-Equity RatioN/A Current Ratio2.63 Quick Ratio2.63Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$23.90 million Price / Sales57.98 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book8.38Profitability EPS (Most Recent Fiscal Year)($1.76) Net Income$-120,460,000.00 Net Margins-139.27% Return on Equity-79.65% Return on Assets-20.41%Miscellaneous Employees78 Outstanding Shares74,459,000Market Cap$1.39 billion Next Earnings Date11/5/2020 (Estimated) OptionableOptionable $18.61 -1.24 (-6.25 %) (As of 09/21/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive DRNA News and Ratings via Email Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter. Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions How has Dicerna Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)? Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DRNA shares have increased by 10.2% and is now trading at $18.61. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Dicerna Pharmaceuticals? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals. When is Dicerna Pharmaceuticals' next earnings date? Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020. View our earnings forecast for Dicerna Pharmaceuticals. How were Dicerna Pharmaceuticals' earnings last quarter? Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.43) EPS for the quarter, missing the consensus estimate of $0.11 by $0.54. The biopharmaceutical company had revenue of $40.45 million for the quarter, compared to analysts' expectations of $76.04 million. Dicerna Pharmaceuticals had a negative return on equity of 79.65% and a negative net margin of 139.27%. View Dicerna Pharmaceuticals' earnings history. What price target have analysts set for DRNA? 11 Wall Street analysts have issued 1 year price targets for Dicerna Pharmaceuticals' stock. Their forecasts range from $25.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' share price to reach $35.30 in the next year. This suggests a possible upside of 89.7% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals. Who are some of Dicerna Pharmaceuticals' key competitors? Some companies that are related to Dicerna Pharmaceuticals include Emergent Biosolutions (EBS), Ultragenyx Pharmaceutical (RARE), BridgeBio Pharma (BBIO), HUTCHISON CHINA/S (HCM), United Therapeutics (UTHR), MorphoSys (MOR), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR), Zai Lab (ZLAB), Arena Pharmaceuticals (ARNA), Evotec (EVTCY), FibroGen (FGEN), Allakos (ALLK), ChemoCentryx (CCXI) and Biohaven Pharmaceutical (BHVN). View all competitors. What other stocks do shareholders of Dicerna Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Gilead Sciences (GILD), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Pfizer (PFE) and Array Biopharma (ARRY). Who are Dicerna Pharmaceuticals' key executives? Dicerna Pharmaceuticals' management team includes the following people: Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory BoardProf. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72) What is Dicerna Pharmaceuticals' stock symbol? Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA." Who are Dicerna Pharmaceuticals' major shareholders? Dicerna Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.61%), Vanguard Group Inc. (4.48%), UBS Group AG (1.83%), Candriam Luxembourg S.C.A. (1.82%), Driehaus Capital Management LLC (1.36%) and Perceptive Advisors LLC (1.07%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View institutional ownership trends for Dicerna Pharmaceuticals. Which institutional investors are selling Dicerna Pharmaceuticals stock? DRNA stock was sold by a variety of institutional investors in the last quarter, including UBS Group AG, Goldman Sachs Group Inc., Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Bank of Montreal Can, ClariVest Asset Management LLC, Cadence Capital Management LLC, and Federated Hermes Inc.. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, and Peter Kolchinsky. View insider buying and selling activity for Dicerna Pharmaceuticals. Which institutional investors are buying Dicerna Pharmaceuticals stock? DRNA stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Candriam Luxembourg S.C.A., Vanguard Group Inc., Prudential Financial Inc., Hudson Bay Capital Management LP, RTW Investments LP, Charles Schwab Investment Management Inc., and Silvercrest Asset Management Group LLC. View insider buying and selling activity for Dicerna Pharmaceuticals. How do I buy shares of Dicerna Pharmaceuticals? Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Dicerna Pharmaceuticals' stock price today? One share of DRNA stock can currently be purchased for approximately $18.61. How big of a company is Dicerna Pharmaceuticals? Dicerna Pharmaceuticals has a market capitalization of $1.39 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe. What is Dicerna Pharmaceuticals' official website? The official website for Dicerna Pharmaceuticals is www.dicerna.com. How can I contact Dicerna Pharmaceuticals? Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected] This page was last updated on 9/22/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
